Robeco Institutional Asset Management B.V. Has $3.54 Million Holdings in Humana Inc. (NYSE:HUM)

Robeco Institutional Asset Management B.V. raised its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 44.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,162 shares of the insurance provider's stock after buying an additional 3,447 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Humana were worth $3,535,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV lifted its holdings in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock valued at $27,000 after buying an additional 61 shares during the period. CarsonAllaria Wealth Management Ltd. lifted its position in shares of Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider's stock valued at $28,000 after buying an additional 39 shares during the last quarter. Atwood & Palmer Inc. acquired a new position in Humana during the 3rd quarter valued at approximately $29,000. Your Advocates Ltd. LLP lifted its position in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the period. Finally, Hantz Financial Services Inc. acquired a new position in Humana in the 2nd quarter worth about $35,000. Institutional investors own 92.38% of the company's stock.

Humana Price Performance

Shares of Humana stock traded up $0.36 on Friday, hitting $288.12. 1,691,681 shares of the company were exchanged, compared to its average volume of 2,587,340. The company has a 50-day moving average price of $289.38 and a 200 day moving average price of $332.67. The stock has a market capitalization of $34.69 billion, a price-to-earnings ratio of 25.52, a price-to-earnings-growth ratio of 2.28 and a beta of 0.52. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $527.18.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to analysts' expectations of $28.66 billion. As a group, sell-side analysts predict that Humana Inc. will post 15.83 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date is Tuesday, December 31st. Humana's dividend payout ratio is currently 31.36%.

Wall Street Analyst Weigh In

A number of brokerages have commented on HUM. KeyCorp started coverage on shares of Humana in a research note on Friday, October 11th. They set a "sector weight" rating on the stock. Truist Financial cut their price target on shares of Humana from $400.00 to $260.00 and set a "hold" rating for the company in a report on Friday, October 11th. JPMorgan Chase & Co. raised their price objective on Humana from $332.00 to $396.00 and gave the stock a "neutral" rating in a report on Wednesday, August 21st. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Humana from $349.00 to $250.00 and set a "hold" rating on the stock in a research report on Thursday, October 3rd. Finally, Oppenheimer cut their price target on Humana from $400.00 to $280.00 and set an "outperform" rating on the stock in a report on Thursday, October 3rd. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Humana presently has a consensus rating of "Hold" and an average target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.